PREMARKET ALERT: Human Genome Sciences (HGSI)

Posted in General 
July 9th, 2009

Human Genome Sciences Inc. (Nasdaq: HGSI) shares are up more than 6 percent to $2.55 on volume of more than 120,000 shares as of about 8:30 a.m. Eastern. The company says data published in The New England Journal of Medicine supports the use of its human monoclonal antibody drug Raxibacumab for the treatment of inhalation anthrax disease. — Mike Tarsala

Comments are closed